Roudinskii Nikita I, Sukhanova Anna L, Kazennova Elena V, Weber Jonathan N, Pokrovsky Vadim V, Mikhailovich Vladimir M, Bobkov Aleksei F
Laboratory of T-Lymphotropic Viruses, D. I. Ivanovsky Institute of Virology, 16 Gamaleya Street, Moscow 123098, Russia.
J Virol. 2004 Oct;78(20):11276-87. doi: 10.1128/JVI.78.20.11276-11287.2004.
To characterize polymorphisms of the subtype A protease in the former Soviet Union, proviral DNA samples were obtained, with informed consent, from 119 human immunodeficiency virus type 1 (HIV-1)-positive untreated injecting drug users (IDUs) from 16 regions. All individuals studied have never been treated with antiretroviral drugs. The isolates were defined as IDU-A (n = 115) and CRF03_AB (n = 4) by using gag/env HMA/sequencing. The pro region was analyzed by using sequencing and original HIV-ProteaseChip hybridization technology. The mean of pairwise nucleotide distance between 27 pro sequences (23 IDU-A and 4 CRF03_AB) was low (1.38 +/- 0.79; range, 0.00 to 3.23). All sequences contained no primary resistance mutations. However, 13 of 23 (56.5%) subtype A isolates bore the V77I substitution known as the secondary protease mutation. V77I was associated with two synonymous substitutions in triplets 31 and 78, suggesting that all V77I-bearing viruses evolved from a single source in 1997. Hybridization analysis showed that 55 of 115 (47.8%) HIV-1 isolates contained V77I, but this variant was not found in any of 31 DNA samples taken from regions, where the HIV-1 epidemic among IDUs started earlier 1997, as well as in any of four CRF03_AB isolates. The results of analysis of 12 additional samples derived from epidemiologically linked subjects showed that in all four epidemiological clusters the genotype of the donor and the recipients was the same irrespective of the route of transmission. This finding demonstrates the transmission of the V77I mutant variant, which is spreading rapidly within the circulating viral pool in Russia and Kazakhstan. The continued molecular epidemiological and virological monitoring of HIV-1 worldwide thus remains of great importance.
为了鉴定前苏联地区A型蛋白酶的多态性,在获得知情同意后,从16个地区的119名未经治疗的1型人类免疫缺陷病毒(HIV-1)阳性注射吸毒者(IDU)中获取了前病毒DNA样本。所有研究对象均未接受过抗逆转录病毒药物治疗。通过使用gag/env HMA/测序,将分离株定义为IDU-A(n = 115)和CRF03_AB(n = 4)。使用测序和原始的HIV蛋白酶芯片杂交技术对蛋白酶原区域进行分析。27个蛋白酶原序列(23个IDU-A和4个CRF03_AB)之间的成对核苷酸距离平均值较低(1.38 +/- 0.79;范围为0.00至3.23)。所有序列均未包含主要耐药突变。然而,23个A型分离株中有13个(56.5%)携带V77I替代,这被称为次要蛋白酶突变。V77I与三联体31和78中的两个同义替代相关,表明所有携带V77I的病毒均在1997年从单一来源进化而来。杂交分析显示,115个HIV-1分离株中有55个(47.8%)含有V77I,但在1997年之前IDU中HIV-1流行较早的地区采集的31个DNA样本中以及4个CRF03_AB分离株中均未发现该变体。对另外12个来自有流行病学关联个体的样本进行分析的结果表明,在所有四个流行病学集群中,无论传播途径如何,供体和受体的基因型均相同。这一发现证明了V77I突变变体的传播,该变体正在俄罗斯和哈萨克斯坦的循环病毒库中迅速传播。因此,持续对全球HIV-1进行分子流行病学和病毒学监测仍然非常重要。